there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.
Company profile
Ticker
LABP
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
815085535
LABP stock data
Latest filings (excl ownership)
DEFM14A
Proxy related to merger
25 Apr 24
10-K/A
2023 FY
Annual report (amended)
16 Apr 24
PREM14A
Preliminary proxy related to merger
15 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
8-K
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
25 Mar 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
21 Mar 24
Transcripts
Latest ownership filings
SC 13D/A
PERCEPTIVE ADVISORS LLC
10 Apr 24
SC 13D/A
Xontogeny, LLC
10 Apr 24
4
Fabio Cataldi
4 Mar 24
4
Gregory Oakes
4 Mar 24
SC 13G/A
Bassaganya-Riera Josep
14 Feb 24
4
Alka Batycky
1 Jun 23
3
Alka Batycky
1 Jun 23
4
TIMOTHY M MAYLEBEN
24 May 23
4
Tiago Girao
24 May 23
4
Christopher Nishan Garabedian
24 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 42.46 mm | 42.46 mm | 42.46 mm | 42.46 mm | 42.46 mm | 42.46 mm |
Cash burn (monthly) | 530.33 k | (no burn) | 1.95 mm | 1.94 mm | 742.67 k | 1.60 mm |
Cash used (since last report) | 3.85 mm | n/a | 14.20 mm | 14.11 mm | 5.40 mm | 11.63 mm |
Cash remaining | 38.60 mm | n/a | 28.26 mm | 28.35 mm | 37.06 mm | 30.82 mm |
Runway (months of cash) | 72.8 | n/a | 14.5 | 14.6 | 49.9 | 19.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 0 |
Closed positions | 12 |
Increased positions | 1 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 6.28 bn |
Total shares | 6.41 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Xontogeny | 3.09 mm | $803.00 k |
Osage University GP III | 1.83 mm | $8.77 mm |
Perceptive Advisors | 1.49 mm | $6.26 bn |
Tower Research Capital | 1.54 k | $6.49 mm |
RY Royal Bank Of Canada | 612.00 | $3.00 mm |
Acadian Asset Management | 134.00 | $0.00 |
JPM JPMorgan Chase & Co. | 59.00 | $247.00 k |
BLK Blackrock | 42.00 | $177.00 k |
UBS UBS Group AG - Registered Shares | 37.00 | $156.00 k |
WFC Wells Fargo & Co. | 9.00 | $38.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Fabio Cataldi | RSU Common Stock | Grant | Acquire A | No | No | 0 | 21,138 | 0.00 | 21,138 |
29 Feb 24 | Gregory Oakes | RSU Common Stock | Grant | Acquire A | No | No | 0 | 54,454 | 0.00 | 54,454 |
30 May 23 | Alka Batycky | Stock Option Common Stock | Grant | Acquire A | No | No | 3.05 | 3,600 | 10.98 k | 3,600 |
23 May 23 | Christopher Nishan Garabedian | Stock Option Common Stock | Grant | Acquire A | No | No | 0.33 | 18,000 | 5.94 k | 18,000 |
News
Nasdaq Turns Higher; Akanda Shares Plunge
25 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Crude Oil Moves Higher; US New Home Sales Fall In February
25 Mar 24
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
25 Mar 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP
23 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LABP, ADTH, MODN, SCX
18 Apr 24
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
16 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT
9 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA
5 Apr 24